Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men

Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study

(2020) Masaki Yoshida et al.   BJU INTERNATIONAL

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)

(2020) Steven A. Kaplan et al.   JOURNAL OF UROLOGY

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy

(2020) Shunye Su et al.   MEDICINE

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)

(2020) Tomonori Yamanishi et al.   NEUROUROLOGY AND URODYNAMICS

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR

(2020) David Staskin et al.   JOURNAL OF UROLOGY

Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals

(2020) Marcus J. Drake et al.   EUROPEAN UROLOGY

Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis

(2020) Menghua Wang et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study

(2020) Satoru Takahashi et al.   LUTS-Lower Urinary Tract Symptoms

The urothelium, the urinary microbioma and men LUTS: a systematic review

(2020) Riccardo Lombardo et al.   Minerva Urologica E Nefrologica

The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis

(2019) Greta Lozano-Ortega et al.   UROLOGY

Comparison in the efficacy of fesoterodine or mirabegron add‐on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies

(2019) Yoshihisa Matsukawa et al.   NEUROUROLOGY AND URODYNAMICS

The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction

(2019) Carlos D'Ancona et al.   NEUROUROLOGY AND URODYNAMICS

A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment

(2019) Benoit Peyronnet et al.   EUROPEAN UROLOGY

Metabolic syndrome and smoking are associated with persistence of nocturia after transurethral resection of the prostate

(2019) Cosimo Nunzio et al.   NEUROUROLOGY AND URODYNAMICS

Treatment Response and Complications after Intradetrusor Onabotulinumtoxin A Injection in Male Patients with Idiopathic Overactive Bladder Syndrome

(2019) Laura Mateu Arrom et al.   JOURNAL OF UROLOGY

Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder

(2019) Mohammad Abrar et al.   UROLOGY

How can we better manage drug‐resistant OAB/DO? ICI‐RS 2018

(2019) Christopher Chermansky et al.   NEUROUROLOGY AND URODYNAMICS

Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex

(2019) Christopher R. Chapple et al.   European Urology Focus

Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH)

(2019) Hidehiro Kakizaki et al.   European Urology Focus

Mirabegron: A Review in Overactive Bladder Syndrome

(2018) Emma D. Deeks   DRUGS

Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature

(2018) Manuela Tutolo et al.   EUROPEAN UROLOGY

EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence

(2018) Arjun K. Nambiar et al.   EUROPEAN UROLOGY

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)

(2018) Christian Gratzke et al.   EUROPEAN UROLOGY

Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men

(2018) Laura N. Nguyen et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction

(2018) M. Samarinas et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction

(2018) Chun-Hou Liao et al.   UROLOGY

Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder

(2018) Pierre-Adrien Leroux et al.   WORLD JOURNAL OF UROLOGY

Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis

(2018) Hsiao-Ling Chen et al.   WORLD JOURNAL OF UROLOGY

OnabotulinumtoxinA injections in men with refractory idiopathic detrusor overactivity

(2018) N Faure Walker et al.   UROLOGY

Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study

(2018) Dong Gil Shin et al.   NEUROUROLOGY AND URODYNAMICS

Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study

(2017) Yoshihisa Matsukawa et al.   INTERNATIONAL JOURNAL OF UROLOGY

How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2

(2017) Apostolos Apostolidis et al.   NEUROUROLOGY AND URODYNAMICS

Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)

(2017) Apostolos Apostolidis et al.   NEUROUROLOGY AND URODYNAMICS

Long-term compliance and results of intravesical botulinum toxin A injections in male patients

(2017) Mohammad S. Rahnama'i et al.   NEUROUROLOGY AND URODYNAMICS

Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?

(2016) Jean-Nicolas Cornu et al.   CURRENT OPINION IN UROLOGY

A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study

(2016) James A. Thomas et al.   EUROPEAN UROLOGY

Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study

(2016) Michael B. Chancellor et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men

(2016) Tomohiro Matsuo et al.   BMC Urology

Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes

(2015) David Habashy et al.   BJU INTERNATIONAL

Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

(2015) Osamu Yamaguchi et al.   BJU INTERNATIONAL

The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB

(2015) Cosimo Nunzio et al.   CURRENT DRUG TARGETS

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment

(2015) E. Ann Gormley et al.   JOURNAL OF UROLOGY

A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction

(2015) Koji Ichihara et al.   JOURNAL OF UROLOGY

Can We Predict Which Patients will Experience Resolution of Detrusor Overactivity after Transurethral Resection of the Prostate?

(2015) Alberto Azoubel Antunes et al.   JOURNAL OF UROLOGY

Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction

(2015) Jeongyun Jeong et al.   UROLOGY

Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data

(2014) Zalmai Hakimi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Prediction of Persistent Storage Symptoms after Transurethral Resection of the Prostate in Patients with Benign Prostatic Enlargement

(2014) Hoon Choi et al.   UROLOGIA INTERNATIONALIS

Detrusor Overactivity Does Not Predict Bothersome Storage Symptoms After Photoselective Vaporization of the Prostate With Lithium Triborate Laser

(2014) Bartosz A. Dybowski et al.   UROLOGY

TRP channels in lower urinary tract dysfunction

(2013) J Franken et al.   BRITISH JOURNAL OF PHARMACOLOGY

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

(2013) Christopher Chapple et al.   EUROPEAN UROLOGY

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

(2013) V. W. Nitti et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Mirabegron for Male Lower Urinary Tract Symptoms

(2013) Oscar Suarez et al.   Current Urology Reports

OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial

(2012) Clare J. Fowler et al.   EUROPEAN UROLOGY

β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men

(2012) Hideo Otsuki et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update

(2011) Anastasios Athanasopoulos et al.   EUROPEAN UROLOGY

Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial

(2011) Hartmut Porst et al.   EUROPEAN UROLOGY

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

(2011) Francisco Cruz et al.   EUROPEAN UROLOGY

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder

(2010) Francois A. Giuliano et al.   BJU INTERNATIONAL

Age and Bladder Outlet Obstruction Are Independently Associated with Detrusor Overactivity in Patients with Benign Prostatic Hyperplasia

(2008) Matthias Oelke et al.   EUROPEAN UROLOGY